Findings in patients from benin with osteomyelitis and polymerase chain reaction-confirmed mycobacterium ulcerans infection

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1256-1264

  Pommelet, Virginie ^a   Vincent, Quentin B ^b,c   FrançoiseArdant, Marie ^g   Adeye, Ambroise ^g   Tanase, Anca ^d   Tondeur, Laura ^a   Rega, Adelaide ^d   Landier, Jordi ^a   Marion, Estelle ^e,g,h   Alcaïs, Alexandre ^b,c,e,f   Marsollier, Laurent ^e,h   Fontanet, Arnaud ^a,f   Chauty, Annick ^g  

^a INSTITUT PASTEUR   (France)

^b Laboratory of Human Genetics of Infectious Diseases Necker Branch Institut National de la Recherche Medicale   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e INSERM   (France)

^f University of Paris Cité   (France)

^g Fondation Raoul Follereau   (Benin)

^h UNIVERSITÉ D'ANGERS   (France)

Author keywords

Buruli ulcer; Mycobacterium ulcerans; osteomyelitis

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BCG VACCINATION; BENIN; BONE INFECTION; BONE RADIOGRAPHY; BURULI ULCER; CASE CONTROL STUDY; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DELAYED DIAGNOSIS; DEMOGRAPHY; ENDEMIC DISEASE; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINOR SURGERY; MYCOBACTERIUM ULCERANS; OSTEOMYELITIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SKIN DEFECT; SURGICAL TECHNIQUE; TRADITIONAL MEDICINE; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY;

ADOLESCENT; BENIN; BURULI ULCER; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; MALE; MYCOBACTERIUM ULCERANS; OSTEOMYELITIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84910150544     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu584     Document Type: Article

References (37)

1. Sopoh GE, Johnson RC, Chauty A, et al. Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis 2007; 13:1374-6.
2. World Health Organization. Buruli ulcer. Available at: http://www.who. int/buruli/en/. Accessed 15 July 2013.
3. Uganda Buruli Group. Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg 1971; 65:763-75.
4. Raghunathan PL, Whitney EA, Asamoa K, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): results from a casecontrol study in Ghana. Clin Infect Dis 2005; 40:1445-53.
5. Johnson RC, Makoutode M, Sopoh GE, et al. Buruli ulcer distribution in Benin. Emerg Infect Dis 2005; 11:500-1.
6. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999; 353:986.
7. Merritt RW, Walker ED, Small PL, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010; 4: e911.
8. Marion E, Eyangoh S, Yeramian E, et al. Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis 2010; 4:e731.
9. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002; 68:4623-8.
10. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13:1653-60.
11. Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 2010; 4: e791.
12. Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg 2008; 102:969-78.
13. Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004; 10:1391-8.
14. van der Werf TS, Stinear T, Stienstra Y, van der Graaf WT, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003; 362:1062-4.
15. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008; 25:447-54.
16. World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers, 2012. Available at: http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402-eng. pdf. Accessed 4 August 2014.
17. Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2010; 52:94-6.
18. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375:664-72.
19. Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-5.
20. Vincent QB, Ardant M-F, Adeye A, et al. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. Lancet Global Health 2014; 2:e422-30.
21. Lagarrigue V, Portaels F, Meyers WM, Aguiar J. Buruli ulcer: risk of bone involvement! apropos of 33 cases observed in Benin. Med Trop (Mars) 2000; 60:262-6. [in French].
22. Pszolla N, Sarkar MR, StreckerW, et al. Buruli ulcer: a systemic disease. Clin Infect Dis 2003; 37:e78-82.
23. Toll A, Gallardo F, Ferran M, et al. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol 2005; 30:649-51.
24. Lewis JA, Miller DR, Davies SG. Osteomyelitis complicating three types of traumatic hand wound. J Wound Care 2004; 13:281-3.
25. Mantero E, Carbone M, Calevo MG, Boero S. Diagnosis and treatment of pediatric chronic osteomyelitis in developing countries: prospective study of 96 patients treated in Kenya. Musculoskelet Surg 2011; 95:13-8.
26. van Schuppen J, van Doorn MM, van Rijn RR. Childhood osteomyelitis: imaging characteristics. Insights Imaging 2012; 3:519-33.
27. World Health Organization. Guidance on sampling techniques for laboratory-confirmation of Mycobatcerium ulcerans infection. 2010. Available at: http:/www.who.int/buruli/Guidance-sampling-techniques-MU-infection.pdf. Accessed 15 July 2013.
28. Eddyani M, Portaels F. Survival of Mycobacterium ulcerans at 37 degrees C. Clin Microbiol Infect 2007; 13:1033-5.
29. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet 2006; 367:1849-58.
30. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369-79.
31. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol 2009; 27:291-305.
32. Peltola H, Paakkonen M. Acute osteomyelitis in children. N Engl J Med 2014; 370:352-60.
33. Stanley CM, Rutherford GW, Morshed S, Coughlin RR, Beyeza T. Estimating the healthcare burden of osteomyelitis in Uganda. Trans R Soc Trop Med Hyg 2010; 104:139-42.
34. Peeters Grietens K, Toomer E, Um Boock A, et al. What role do traditional beliefs play in treatment seeking and delay for Buruli ulcer disease? insights from a mixed methods study in Cameroon. PLoS One 2012; 7:e36954.
35. Portaels F, Aguiar J, Debacker M, et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diagn Lab Immunol 2002; 9:1389-91.
36. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer): first results of a trial in Uganda. Lancet 1969; 1:111-5.
37. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-80.